Like bispecific antibody, CD33/TIM3 or CLL1/TIM3 may serve as viable targets to improve treatment efficiency while limiting toxicity during CAR-T therapy in AML patients. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.